FDA Put Brakes On Penny Stock Kezar Life Sciences' Mid-Stage Study For Lead Development Candidate After Patient Deaths – Benzinga

The FDA has halted a mid-stage study for Kezar Life Sciences’ lead development candidate following patient deaths. The penny stock company is facing setbacks as the regulatory agency puts the brakes on their study.